A New Potent Inhibitor against α-Glucosidase Based on an In Vitro Enzymatic Synthesis Approach
Molecules · 16.02.2024 · 29 (4) · 878
DOI: 10.3390/molecules29040878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 16.02.2024. Verfasst von Huanyu Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The national key research and development program, ability establishment of sustainable use for valuable Chinese medicine resources.
Abstract (Originalsprache)
Inhibiting the activity of intestinal α-glucosidase is considered an effective approach for treating type II diabetes mellitus (T2DM). In this study, we employed an in vitro enzymatic synthesis approach to synthesize four derivatives of natural products (NPs) for the discovery of therapeutic drugs for T2DM. Network pharmacology analysis revealed that the betulinic acid derivative P3 exerted its effects in the treatment of T2DM through multiple targets. Neuroactive ligand–receptor interaction and the calcium signaling pathway were identified as key signaling pathways involved in the therapeutic action of compound P3 in T2DM. The results of molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations indicate that compound P3 exhibits a more stable binding interaction and lower binding energy (−41.237 kcal/mol) with α-glucosidase compared to acarbose. In addition, compound P3 demonstrates excellent characteristics in various pharmacokinetic prediction models. Therefore, P3 holds promise as a lead compound for the development of drugs for T2DM and warrants further exploration. Finally, we performed site-directed mutagenesis to achieve targeted synthesis of betulinic acid derivative. This work demonstrates a practical strategy of discovering novel anti-hyperglycemic drugs from derivatives of NPs synthesized through in vitro enzymatic synthesis technology, providing potential insights into compound P3 as a lead compound for anti-hyperglycemic drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
- Key Laboratory of Systems Bioengineering, Ministry of Education, Tianjin University, Tianjin 300072, China.
- School of Traditional Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301600, China.
ORCID-Profile: Yaowu Su, Wenyuan Gao
Förderung
- The national key research and development program
- ability establishment of sustainable use for valuable Chinese medicine resources
Zitieren
APA
Zhang, H., Che, X., Jing, H., Su, Y., Yang, W., Wang, R., Zhang, G., Meng, J., Yuan, W., Wang, J., & Gao, W. (2024). A New Potent Inhibitor against α-Glucosidase Based on an In Vitro Enzymatic Synthesis Approach. Molecules, 29(4), 878. https://doi.org/10.3390/molecules29040878
Vancouver
Zhang H, Che X, Jing H, Su Y, Yang W, Wang R, et al. A New Potent Inhibitor against α-Glucosidase Based on an In Vitro Enzymatic Synthesis Approach. Molecules. 2024;29(4):878. doi:10.3390/molecules29040878
BibTeX
@article{Zhang2024,
author = {Zhang, Huanyu and Che, Xiance and Jing, Hongyan and Su, Yaowu and Yang, Wenqi and Wang, Rubing and Zhang, Guoqi and Meng, Jie and Yuan, Wei and Wang, Juan and Gao, Wenyuan},
title = {A New Potent Inhibitor against α-Glucosidase Based on an In Vitro Enzymatic Synthesis Approach},
journal = {Molecules},
year = {2024},
volume = {29},
number = {4},
pages = {878},
doi = {10.3390/molecules29040878}
}
EUVIMED